Eric Topol and Lee Hood — Two Scientific Luminaries on Longevity and Prevention

World-renowned physician-scientist Dr. Eric Topol joined ISB Co-founder Dr. Lee Hood for a wide-ranging virtual discussion about Topol’s new book, Super Agers, and the evidence-based science of longevity, prevention, and healthspan. The November 4, 2025, event united two figures whose careers have helped define modern medicine.

Topol, a cardiologist and geneticist, has led transformative clinical trials, advanced genomic and digital medicine, and has become one of the field’s most respected voices for patient empowerment and data transparency.

Hood pioneered technologies that made it possible to sequence the human genome and championed systems biology and the P4 model of medicine — predictive, preventive, personalized, and participatory.

In Super Agers, Topol brings those worlds together, blending genomics, AI, and lifestyle science to illuminate how we can extend our healthspan — the years lived in good health and functional independence — rather than simply lifespan.

“We’ve talked about prevention for decades,” Topol said, “but for the first time we have the tools to actually achieve it.”

A Data-Driven Path to Prevention

Topol pointed to multimodal AI that integrates layers of biological data — from polygenic risk scores to organ “clocks” derived from proteins — and enables physicians to predict disease onset years in advance.

“We can prevent the big three age-related diseases — cardiovascular, cancer, and neurodegenerative — by identifying high-risk individuals early and intervening before disease develops,” he said.

P4 and the Human Element

Hood noted that this approach aligns with the vision that launched ISB. “P4 has always been about taking a systems approach to human health,” he said. The “participatory” element, Hood added, remains the hardest. “How do you persuade people to do what’s good for them?” he asked.

Topol agreed. “That’s the big challenge,” he said. “But when you give someone their own data — say, a polygenic risk score showing high likelihood of Alzheimer’s — behavior changes. It’s far more motivating than a generalized public-health message.”

Separating Substance from Hype

Throughout the discussion, both scientists returned to the importance of evidence-based practice. “There’s so much bunk out there,” Topol said, citing the booming market for unproven anti-aging supplements and procedures. “Show me the data. That’s what separates substance from hype.”

The conversation also covered the fundamentals of healthy aging — regular aerobic and strength exercise, anti-inflammatory diets such as the Mediterranean model, and deep, consistent sleep.

“If you just start doing these things at age 50,” Topol said, “the data show you can add seven to 10 more years of healthy life.”

Innovation and Access Must Advance Together

Later, the pair discussed groundbreaking therapies such as GLP-1 drugs and CRISPR-based genome editing, and how these advances, along with massive population studies like All of Us, are reshaping what’s possible in prevention. Yet both stressed that equitable access must accompany innovation.

“Longevity shouldn’t be just for the affluent,” Topol said. “The goal is to make low-cost, high-impact prevention available to everyone.”

The conversation closed where it began — with optimism. “It’s going to take a village to make these changes,” Hood said, “but they’re inevitable. The only question is how long we’ll have to wait.”

You can watch the conversation in full here, or by clicking play on the video at the top of this page.

Follow Dr. Eric Topol on Substack (Ground Truths), X, and Bluesky.